Literature DB >> 11376801

Disruption of the ATM gene in breast cancer.

Y Lu1, A Condie, J D Bennett, M J Fry, M R Yuille, J Shipley.   

Abstract

Mutations in the ATM gene, which maps to 11q22-23, cause the multisystem recessive syndrome ataxia-telangiectasia (AT). Breast cancer has been reported in AT patients and carriers. Sporadic breast cancer is associated with loss of heterozygosity at or in the region of ATM and chromosomal abnormalities involving 11q23. We have investigated the chromosomes, nuclei and released chromatin fibers from nine primary breast carcinoma and eight cell lines by fluorescence in situ hybridization with four fluorochrome-labeled cosmids spanning the ATM gene. The ATM gene was disrupted in one primary breast carcinoma and in the cell lines MDA-MB-231 and MCF-7. The role of these aberrations in breast carcinomas, which may lead to gene dosage or dominant negative effects on gene function, requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11376801     DOI: 10.1016/s0165-4608(00)00401-5

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes.

Authors:  Roger A Greenberg; Bijan Sobhian; Shailja Pathania; Sharon B Cantor; Yoshihiro Nakatani; David M Livingston
Journal:  Genes Dev       Date:  2006-01-01       Impact factor: 11.361

2.  Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.

Authors:  Michael A Batey; Yan Zhao; Suzanne Kyle; Caroline Richardson; Andrew Slade; Niall M B Martin; Alan Lau; David R Newell; Nicola J Curtin
Journal:  Mol Cancer Ther       Date:  2013-03-19       Impact factor: 6.261

3.  Sweet Wormwood and Tortoise Shell Decoction (Thanh Hao Miet Giap Thang) Induces DNA Damage, S-Phase Arrest, and Apoptosis in MCF-7 Cells via ATR-CHK1 Signaling Pathway.

Authors:  Hoang Tam Nguyen Thai; Thuy Vy Nguyen; Thuy Duong Ho Huynh
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-05       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.